Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baillie CT (1995) Tumour vasculature – a potential therapeutic target. Anti Cancer Drugs 6: 438
Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843–1849
Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808–812
Boehm T, Folkman J, Browder T and O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404–407
Brekken J, Zou H, Kolis S, Wood A, Webber S, Appelt K and Shalinsy DR (1999) Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Proc Am Ass Cancer Res 40: 441 (abstract)
Brem S (1998) Angiogenesis antagonists: current clinical trials. Angiogenesis 2: 9–20
Cao Y and Cao R (1999) Angiogenesis inhibited by drinking tea. Nature 398: 381
Cohen J (1999) Behind the headlines of endostatin's ups and downs. Science 283: 1250–1251
D'Amato RJ (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082
Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M and Sukhatme VP (1999a) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189–197
Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M and Sukhatme VP (1999b) Endostatin induces endothelial cell apoptosis. J Biol Chem 274: 11721–11726
Eliceiri BP and Cheresh DA (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103: 1227–1230
Harris RF (1999) Gristle for the mill. Curr Biol 9: R232
Hennequin LF, Thomas AP, Johnstone C, Ple P, Stokes ESE, Ogilvie DJ, Dukes M and Wedge SR (1999) ZD4190: The design and synthesis of a novel, orally active VEGF receptor tyrosine kinase inhibitor. Proc Am Ass Cancer Res 40: 457 (abstract)
Huang XM, Molema G, King S, Watkins L, Edgington TS and Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547–550
Hunter J (1787). Lectures on the Principles of Surgery Vol. 1, London
Kerbel RS and Pluda J (1999). Preclinical and clinical aspects of anti-angiogenic strategies to treat cancer, American Society of Clinical Oncology, 35th Annual Meeting: Atlanta
Kolata G (1998) A cautious awe greets drugs that eradicate tumors in mice. The New York Times, (May 3).
Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ and Peters KG (1998) Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49–58
Mordenti J, Thomsen K, Licko V, Chen H, Meng YG and Ferrara N (1999) Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27: 14–21
Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW and Pizzo SV (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811–2816
Ogilvie DJ, Wedge SR, Dukes M, Kendrew J, Curwen JO, Thomas AP, Hennequin LF, Ple P, Stokes ESE, Johnstone C, Wadsworth P, Richmond GHP and Curry B (1999) ZD4190: An orally administered inhibitor of VEGF signalling with pan-xenograft anti-tumor activity. Proc Am Ass Cancer Res 40: 458 (abstract)
O'Reilly MS (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exs 79: 273–294
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285
Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D and Kerbel RS (1995) Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263–277
Rowe PM (1999) What is all the hullabaloo about endostatin?. Lancet 353: 732
Sim BKL, Fogler WE, Zhou XH, Liang H, Madsen JW, O'Reilly MS, Panigrahy D and Fortier AH (1999) Potent inhibition of experimental metastases and primary tumors by recombinant human endostatin that is suitable for human use. Proc Am Ass Cancer Res 40: 4092 (abstract)
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG and Crews CM (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099–6103
Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA, Moser TL, Asplin I, Hojrup P, Everitt L, Hubchak S, Schnaper HW and Pizzo SV (1999) Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation: angiostatin binds ATP synthase on the surface of human endothelial cells. Biochem J 340: 77–84
Talbot DC and Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32a: 2528–2533
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716
Van der Schaft DWJ, Barendsz-Janson AF, Hillen HFP and Griffioen AW (1999) Tamoxifen inhibits human angiogenesis. Proc Am Ass Cancer Res 40: 3004 (abstract)
Wadman M (1998) Cancer ‘cure' article stirs up hot debate. Nature 393: 104–105
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Oehler, M., Bicknell, R. The promise of anti-angiogenic cancer therapy. Br J Cancer 82, 749–752 (2000). https://doi.org/10.1054/bjoc.1999.0991
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0991
This article is cited by
-
Generation of inactivated IL2RG and RAG1 monkeys with severe combined immunodeficiency using base editing
Signal Transduction and Targeted Therapy (2023)
-
Non-proteolytic calpain-6 interacts with VEGFA and promotes angiogenesis by increasing VEGF secretion
Scientific Reports (2019)
-
Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers
Current Treatment Options in Oncology (2015)
-
Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells
Molecular and Cellular Biochemistry (2014)
-
From humanized mice to human disease: guiding extrapolation from model to target
Biology & Philosophy (2013)